AVI-535B

AVI-535B is an investigational **bispecific therapeutic antibody** being developed by **AbVision** for **liquid tumors**. Based on the provided evidence, it is designed as an **anti-CD47 bispecific antibody paired with a T-cell checkpoint inhibitor arm**, aiming to both block the CD47 \"don't eat me\" signal on tumor cells and enhance anti-tumor immune responses. By inhibiting CD47-mediated suppression of macrophage phagocytosis and combining this with T-cell checkpoint modulation, AVI-535B is intended to promote innate and adaptive antitumor immunity in hematologic malignancies. The program appears to be preclinical or early development and has been described by the company as available for partnering and out-licensing.